Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STTEPP: Lacosamide in Painful Chronic Pancreatitis
NCT05603702Phase 1Active, not recruiting
- Sponsor
- Indiana University
- Start
- Mar 2023
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lacosamide in chronic pancreatitis (CP), opioid-induced hyperalgesia (OIH) and chronic pain, sponsored by Indiana University. Primary endpoints: Dose-Limiting Toxicity, Tolerability (Compliance) and 2 more. Started Mar 2023; status: active, not recruiting.
02
Drugs
lacosamide
03
Conditions
chronic pancreatitis (CP)opioid-induced hyperalgesia (OIH)chronic pain
Beyond the preview
Go deeper on NCT05603702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05603702.